malignant melanoma skin cancer
Conditions
Interventions
None listed
Sponsors
Leids Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Adults (above 18 years) Diagnosed with metastasized melanoma Starting immunotherapy within the next two weeks. Treatment regimen: pembrolizumab 3 or 6-weekly, nivolumab 4-weekly, ipilimumab/nivolumab 3-weekly.
Exclusion criteria
Exclusion criteria: Age under 18 years Obvious intellectual impairment Insufficient knowledge of the Dutch language. Patients with no or very short hair
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main study parameter is whether chronic stress is related to response 3 and 6 months after the start of immunotherapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| Demographic (age, gender, social relational variables) and medical variables (type, duration and doses of immunotherapy, immunotherapy related adverse events, use of immunosuppressive agents, LDH, pain, WHO-performance, location of metastases, oral contraceptive use) will be collected from medical records and by asking some additional questions at baseline. | — |
Countries
Netherlands
Outcome results
None listed